EU/3/19/2230

About

On 16 December 2019, orphan designation EU/3/19/2230 was granted by the European Commission to Argenx B.V.B.A., Belgium, for efgartigimod alfa for the treatment of immune thrombocytopenia. 

Key facts

Active substance
Efgartigimod alfa
Disease / condition
Treatment of immune thrombocytopenia
Date of first decision
16/12/2019
Outcome
Positive
EU designation number
EU/3/19/2230

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Argenx B.V.B.A.
Technologiepark-Zwijnaarde 30
9052 Zwijnaarde
Oost-Vlaanderen
Belgium
Tel: +32 497 62 46 13
E-mail: info@argenx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating